cvot tirzepatide SURPASS-CVOT shows delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow 💡 New insight in diabetes

[DOI] [PMC free article] [PubMed] [Google Scholar] Wang W, Zhang H, Gao H, Kubo H, Berretta RM, Chen X, Houser SR (2010) beta1-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways

The goal isnt dramatic weight reduction, but gentle recalibration a quieter support for patients who: Are already within a healthy weight range but struggle with subtle hormonal weight fluctuations Experience puffiness or facial bloating unrelated to diet Want to reduce fat while retaining or building muscle mass Want to enhance treatments for hormonal challenges like PCOS and autoimmune challenges like lymphadema Prefer a metabolically sound approach to aesthetic maintenance as they age This strategy may also appeal to patients seeking preventative aging support

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options

Its not a straightforward 'yes' or 'no'